Data from TCGA analyses underline that reduced VTN expression is aligned with more advanced tumor stages: a particularly stark prognosis difference was observed in stage 4 pancreatic cancer patients, where low VTN expression was connected to significantly worse outcomes than seen with high expression levels (Figure 2K). Here, VTN is linked to familial pancreatic carcinoma.